BioMed Central

BMC Clinical Pathology

Research article

Serum S100B levels after meningioma surgery: A comparison of two laboratory assays
Sharon Einav*1, Eyal Itshayek†2, Jeremy D Kark†3, Haim Ovadia†4, Carolyn F Weiniger†5 and Yigal Shoshan†6

Address: 1The Intensive Care Unit of the Shaare Zedek Medical Center, affiliated with the Hebrew University, POB 3235, Jerusalem 91031, Israel, 2The Department of Neurosurgery, Hadassah Hebrew University Medical Center, Jerusalem, Israel, 3The Epidemiology Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel, 4The Department of Neurology, Agnes Ginges Center for Human Neurogenetics, Hadassah Hebrew University Medical Center, Jerusalem, Israel, 5The Department of Anesthesia, Hadassah Hebrew University Medical Center, Jerusalem, Israel and 6The Department of Neurosurgery, Hadassah Hebrew University Medical Center, Jerusalem, Israel

Email: Sharon Einav* - einav_s@szmc.org.il; Eyal Itshayek - eyalit@md.huji.ac.il; Jeremy D Kark - jeremy1@vms.huji.ac.il; Haim Ovadia - ovadia@hadassah.org.il; Carolyn F Weiniger - carolynfspencer@gmail.com; Yigal Shoshan - shush@hadassah.org.il

* Corresponding author †Equal contributors

Abstract

Background: S100B protein is a potential biomarker of central nervous system insult. This study quantitatively compared two methods for assessing serum concentration of S100B.

Methods: A prospective, observational study performed in a single tertiary medical center. Included were fifty two consecutive adult patients undergoing surgery for meningioma that provided blood samples for determination of S100B concentrations. Eighty samples (40 pre-operative and 40 postoperative) were randomly selected for batch testing. Each sample was divided into two aliquots. These were analyzed by ELISA (Sangtec) and a commercial kit (Roche Elecsys®) for S100B concentrations. Statistical analysis included regression modelling and Bland-Altman analysis.

Results: A parsimonious linear model best described the prediction of commercial kit values by those determined by ELISA (y = 0.045 + 0.277*x, x = ELISA value, R² = 0.732). ELISA measurements tended to be higher than commercial kit measurements. This discrepancy increased linearly with increasing S100B concentrations. At concentrations above 0.7 μg/L the paired measurements were consistently outside the limits of agreement in the Bland-Altman display. Similar to other studies that used alternative measurement methods, sex and age related differences in serum S100B levels were not detected using the Elecsys® (p = 0.643 and 0.728 respectively).

Conclusion: Although a generally linear relationship exists between serum S100B concentrations measured by ELISA and a commercially available kit, ELISA values tended to be higher than commercial kit measurements particularly at concentrations over 0.7 μg/L, which are suggestive of brain injury. International standardization of commercial kits is required before the predictive validity of S100B for brain damage can be effectively assessed in clinical practice.

Published: 19 September 2008

BMC Clinical Pathology 2008, 8:9 doi:10.1186/1472-6890-8-9

Received: 19 December 2007
Accepted: 19 September 2008

This article is available from: http://www.biomedcentral.com/1472-6890/8/9

© 2008 Einav et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background
Protein S100 is an acidic, disulfide-linked, dimeric, calcium-binding, low molecular weight protein. The beta subtype of this protein exists in astrocyte cells in relatively high concentrations. Rises in serum concentrations of S100B have been shown to relate to clinical evidence of CNS damage in the three accepted models of brain injury in humans-trauma [1-3], ischemia [4] and hypoxia [5]. Significantly higher concentrations of S100B have been demonstrated in brain death [3] and in non survivors from cardiopulmonary arrest, compared to survivors [5,6].

The value of using S100B as an indicator of neurological injury in the clinical setting is limited by the relatively high cost and lengthy performance time of the enzyme-linked immunosorbent assay (ELISA) (currently considered the best method of analysis), poor substantiation of reference levels, lack of standardization of serum S-100B testing and the paucity of data regarding the relationship between measurement methods. Most studies demonstrating the potential diagnostic value of serum S-100B in neurological diseases used an ELISA method (Sangtec Medical) [1,5,7,8]. Recently a kit for rapid quantification of S-100B in human serum has become available (Roche Pharmaceuticals, Elecsys®).

The current study was designed to quantitatively compare the commercially available Elecsys® assay for serum S100B protein concentrations with the gold standard ELISA method and to examine whether this test detects sex- and age-related differences in serum S100B protein concentrations similar to those demonstrated with ELISA by Gazzolo et al. [9] and Nyberg et al. [10] in pediatric populations.

Methods
Sampling technique
Following institutional review board approval (Hadassah Hebrew University Medical Center, reference number 14–19/12/03) as well as individual patient informed consent, 52 consecutive adult patients aged 18–80 who underwent supratentorial meningioma surgery over a 10 month period provided pre- and post operative blood samples for analysis of S100B concentrations.

Blood samples were drawn into sterile, preservative-free vacuum containers for the evaluation of S100B in the perioperative period as described elsewhere [11]. For the purpose of the current study, samples drawn prior to surgery (after insertion of an intravenous cannula upon admission) and immediately after surgery were used. These sampling times were selected based on the assumption that the broadest range of serum concentrations would be obtained between the baseline measurement and the measurement at maximal proximity to surgical insult to the central nervous system. Previous data have demonstrated that at this time S100B concentrations are highly correlated with post-cranietomy neurological deterioration and unfavorable 6-month outcome [12]. Since the ELISA array allows batch testing of forty samples at a time, eighty samples were selected at random for the current study, 40 pre-operative and 40 postoperative.

Laboratory testing and workup of blood samples
Blood samples were first allowed to clot for 30 min at room temperature and then centrifuged. Following centrifugation for 15 minutes at 2000 rpm, serum samples were stored at -70 °C for up to ~3 months for batch analysis. The serum samples were then thawed to room temperature, divided into two aliquots and analyzed in parallel by the ELISA and Elecsys® methods. Diluted serum was used for higher values in both assays.

Assessment by ELISA
Testing was performed using the Sangtec 100 ELISA immunosorbent assay for quantitative measurement of S100B protein in human serum (DiaSorin Inc., Stillwater, Minnesota, USA). Each sample was incubated together with an appropriate marker. Washout was performed with a buffer and tetramethylbenzidine was added as a substrate. Following further incubation a tetramethylbenzidine-arresting substance was added. Spectrophotometric reading of light absorbance at 450 nm was performed. Calculation of the result was performed using a cubic spline algorithm. The calculation range is accurate to a measured concentration of 5 μg/L.

Assessment by Elecsys®
Testing was performed using the Roche Elecsys® S100 reagent kit (assay duration 18 minutes, measuring range 0.005–39 μg/L, cross reactivity against S100α < 1%). Less than 24 hr prior to testing calibration was performed per reagent kit and control values were determined to be within the limits required for calibration (0.206 μg/L and 2.54 μg/L). The test kit is based on the sandwich principle; the 1st incubation is performed with a biotinylated monoclonal S100-specific antibody and a monoclonal S100-specific antibody labeled with a ruthenium complex react to form a sandwich complex. The 2nd incubation: After addition of streptavidin-coated microparticles the complex becomes bound to the solid phase via interaction of biotin and streptavidin. The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell. Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier. Results are determined via a calibration curve which is instrument-specifically generated by 2-
point calibration and a master curve provided via the reagent barcode.

The two laboratory analyses were performed by different technicians in different times. Both were blinded to the results of the alternative method.

**Statistical analysis**

In the first stage, several regression models were used to examine the Elecsys® method as a function of the ELISA method using all the samples. These included linear, quadratic, cubic, logarithmic, inverse, compound, power, and growth. Among those models with the best fit (judged by the R² value) the most parsimonious was chosen. In the second stage, Bland-Altman analyses [13] were used to compare the quantification of S100 between Elecsys® and ELISA and to detect the existence of systematic errors. The statistical analyses were performed using SPSS 12 software (SPSS Inc, Chicago, IL). The study endpoint was examination of the relationship between the two test methods.

Preoperative samples were used for detection of age- and sex-related changes in serum S-100B levels using the Elecsys® assay. Statistical analyses included the Mann-Whitney test for comparison between sexes, the Spearman correlation coefficient to evaluate correlation between serum S100B and age and post-hoc ANOVA to test for differences between serum S100B levels and age groups.

**Results**

**Quantitative comparison between the two methods**

The best fitting models that assessed Elecsys® values as a function of ELISA values were linear, quadratic and cubic regressions, with R² values of 0.732, 0.752 and 0.753 respectively. As the R² values were very similar, the more parsimonious (in terms of the number of parameters in the model) linear model was selected to represent the relationship between the two test methods. The formula for the regression line of the relationship between the two test methods was $y = 0.045269 + 0.276976x$, with $x$ = ELISA value (Figure 1).

The mean difference in measurement between the two tests (ELISA minus Elecsys®) was $0.214 \pm 0.277 \, \mu g/L$. However, this value is determined by the distribution of the measured concentrations (i.e. the patient mix) with the discrepancy being a linear function of the S100B concentration. The Bland-Altman analysis clearly demonstrated that the values determined by ELISA were higher than by Elecsys®, with the discrepancy increasing in linear mode as the S100B concentration increased so that the ELISA values markedly exceeded the Elecsys® values at the higher concentrations (Figure 2). The degree of discrepancy was very large (>2 SD) at values above 0.7 μg/L (i.e. in the region of values suggestive of brain injury).
No statistically significant sex difference was noted in serum S100B concentrations measured by the Elecsys® method (p = 0.643), nor was there a correlation between S100B concentration and age (p = 0.728) (figure 3).

**Discussion**

The current study provides a quantitative comparison of two tests for measuring the serum concentration of S100B; ELISA and the commercially available Elecsys®. In terms of R² and the number of parameters in the model, the linear model provided the best fit for the relationship between the results achieved by these tests. However, in our hands ELISA measurements were higher than Elecsys® measurements and particularly so at the higher values, where the differences in the measurements made using the two methods were consistently outside the limits of agreement (2 SDs) as seen in the Bland-Altman display.

Mussack et al. [14] performed a similar analysis in a group of patients undergoing carotid revascularization. With the exception of two patients with ongoing damage, the results of ELISA testing in their series were curtailed at 0.4 \( \mu \)g/L whereas the current paper describes ranges up to 1.2 \( \mu \)g/L. In contrast with our study, Mussack et al. found small, inconsistent mean differences between the methods and little or no change in the difference between methods with increasing S100B concentrations. It is precisely the divergence at higher values reported in our paper (i.e. those more likely to be associated with brain damage) that may cause misclassification of patient status and prognosis; hence the need for standardization. The current paper relates to brain damage as a result of an intracranial operative procedure and may therefore be more pertinent to the range of test values to be expected in direct injury to the brain.

Sex and age related differences in serum S100B levels were not detected using the Elecsys®. This result is consistent with other studies that used alternative measurement methods which demonstrated no sex and age differences in normal adult populations [10,15,16], contrary to pediatric populations [9,10].

There are several subunits of S100 proteins [17], many of which are expressed selectively by specific cell types. The B subunit of the S100 protein (S100B) is found in particularly high concentrations in astroglial cells of the central nervous system and is therefore often referred to as Astrocyte Derived Growth Factor [18,19]. S100B is implicated in the coordinated development and maintenance of the central nervous system; it stimulates differentiation of immature neurons [18-23], promotes cell survival [23,24], induces neurite extension [25] and enhances glial cell proliferation. Observations of higher S100B concentrations humans in infants and adolescence have led some researchers to suggest that the release of this neurotrophic factor decreases as the brain matures [9,10].

Serum S100B concentrations rise in clinical situations representing the three models of human brain injury – trauma [1-3], ischemia [4,26] and hypoxia [5,27]. The degree of elevation is probably related to the severity of blood-brain barrier disruption [28,29]. Although S100B is eliminated by the kidneys, in-vivo studies have not shown a detectable rise in S100B concentration in renal failure, probably due to its estimated 2 hour biological half life [30]. Prolonged post-insult elevation of serum S100B concentrations therefore most probably reflects ongoing central nervous system damage.

Routine use of S100B for early diagnosis of brain injury remains limited for a number of reasons. Lack of specificity for the biologically active dimeric form of the S-100B molecule using the actually available assays is a major problem. This protein can be released from extracerebral tissue, particularly after surgery [31], potentially confounding the association with brain injury and resulting in misclassification. S100B can be released from the heart or mediastinum [32,33] and exists in adipose tissue [34,35], skin, testes [34], skeletal muscle [36] and placental tissue [37,38], albeit in significantly lower concentrations than in brain tissue. The definition of “normal” values in humans has yet to be established in each assay and cutoff values for diagnosis and quantification of the...
presence and extent of brain injury remain undefined. Clinical applicability is also limited by the lack of standardization. Different laboratories using the same kit produced substantially different values [5,6,39,40] and between-kit variance may be even larger.

Elecsys® analysis requires an electrochemiluminescence measuring cell. Apart from the initial centrifuging, testing is fully automated; thus only a few minutes of laboratory staff time are needed for analysis. The reagent kit suffices for up to 100 tests. Calibration is required once monthly and requires two calibration standards in duplicate (4 tests). Two control tests are required daily (2 tests). The real cost of any test is subject to kit yield which depends on several variables (e.g. daily number of tests, calibration and quality control procedures). Calculated yield may be therefore be greatly affected by internal laboratory regulations. Kit yield is close to maximal at 20 tests per day, at which point additional costs are almost negligible (Table 1). In 2008 the local price for an Elecsys S100 kit was 1528 €. Thus, the theoretical price per test was 15.28 €. For a daily routine of 5 reported results (kit yield 0.6451) the real price per test was 23.69 € and for a daily routine of 12 reported results (kit yield 0.8235) the real price per test was 18.55 €. Additional costs of calibrator and control materials should be noted: The estimated consumption of S100 calibrator (price 80.00 €/pack) and control (price 189.00 €/pack) is 2 and 3 packs/year accordingly, yielding additional estimated costs of 727 €/year. Analysis of S100B levels by ELISA requires specialized equipment, a substantial amount of laboratory technician time (approximately 90 minutes per test) and the test kit (which costs 1257 €) usually allows for performance of 40 tests. ELISA measurement remains the gold standard for S100B measurements. However, widespread use of ELISA remains limited by cost/benefit considerations, mainly due to its time-consuming nature.

This study provides an assessment of the relationship between two currently used laboratory methods but does not address the diagnostic accuracy of either (i.e. sensitivity or specificity, optimal cutoff points). The inequality demonstrated between the tests at higher S100 values may have important implications for its use both as a prognostic marker and for clinical diagnosis as different cutoff points may be needed for the different test kits – an overtly undesirable clinical situation. Coefficients of variation are not given for the measurement methods. One should also exercise caution in extrapolating the findings of this study to concentrations of S100B higher than those included in the study.

Clinical tools for early diagnosis of brain damage in critically ill patients are lacking. Physical examination and intuitive prediction are often the mainstays for both diagnostic and treatment decisions in these patients. This is a far from optimal situation in the intensive care environment where judicious allocation of hospital resources is required; survival with overwhelming residual neurological disability and absent or poor quality of life following insult to the central nervous system incurs expensive in- and out-of-hospital therapy and high indirect costs [40-45].

Table 1: Elecsys® rack-pack yield for 28 days.

| n tests | For clinical use daily | For clinical use monthly | For calibration | For Quality Control | Total | Kit yield |
|---------|------------------------|--------------------------|----------------|---------------------|-------|-----------|
| 1       | 28                     | 16                       | 56             | 101                 | 0.28  |
| 2       | 56                     | 16                       | 56             | 130                 | 0.43  |
| 3       | 84                     | 16                       | 56             | 159                 | 0.53  |
| 4       | 112                    | 16                       | 56             | 188                 | 0.60  |
| 5       | 140                    | 16                       | 56             | 217                 | 0.65  |
| 10      | 280                    | 16                       | 56             | 362                 | 0.77  |
| 15      | 420                    | 4                        | 56             | 495                 | 0.85  |
| 20      | 560                    | 4                        | 56             | 640                 | 0.88  |
| 25      | 700                    | 4                        | 56             | 785                 | 0.89  |
| 30      | 840                    | 4                        | 56             | 930                 | 0.90  |
| 40      | 1120                   | 4                        | 56             | 1220                | 0.92  |
| 50      | 1400                   | 4                        | 56             | 1510                | 0.93  |
| 60      | 1680                   | 4                        | 56             | 1800                | 0.93  |
| 70      | 1960                   | 4                        | 56             | 2090                | 0.94  |
| 80      | 2240                   | 4                        | 56             | 2380                | 0.94  |
| 90      | 2520                   | 4                        | 56             | 2670                | 0.94  |
| 100     | 2800                   | 4                        | 56             | 2960                | 0.95  |

Data are correct provided manufacturer specifications and recommendations are followed. Kit yield is close to maximal at 20 tests per day, at which point additional costs are close to negligible.
Despite its limitations, serum S100B, one of the most studied biomarkers of brain damage in the clinical setting, is currently the only one of which we are aware that holds promise as an early marker of brain damage and a predictor of probability of survival and severe neurological disability. Our study points to some shortcomings of currently available measurement methods and to the need for better definition of reference values and for international standardization of commercial kits so that the predictive validity of S100B can be effectively assessed in clinical practice.

Conclusion

Although a general linear relationship exists between serum S100B concentrations measured by ELISA and a commercially available kit, ELISA measurements tended to be higher than commercial kit measurements particularly in concentrations over 0.7 μg/L, which are suggestive of brain injury. International standardization between methods of S100B measurements is required to enable effective assessment of the predictive validity of S100B in clinical practice.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

SE, YS and JDK are responsible for conceiving and designing the study. EI acquired the data. SE performed data analysis under expert statistical supervision and drafted the paper. JDK assisted in interpretation of the data and provided critical revision of the article together with HO and CFW.

Acknowledgements

This study was supported by a grant from the Chief Scientist of the Ministry of Health, Jerusalem, Israel. Grant number: 5397.

Our gratitude is also given to Dr. Mario Baras who provided expert statistical consult for this paper.

References

1. Pelinka LE, Toegel E, Mauritz W, Redl H: Serum S100β: A marker of brain damage in traumatic brain injury with and without multiple trauma. Shock 2003, 19:195-200.
2. Berger RP, Pierce MC, Wisniewski SR, Adelson PD, Kochanek PM: Serum S100β concentrations are increased after closed head injury in children: A preliminary study. J Neuropaediatrics 2002, 19:1405-1409.
3. Dimopoulou I, Korfas S, Dafni U, Anthi A, Psachoulia C, Jullien G, Sakas DE, Roussos C: Protein S100β serum levels in trauma-induced brain death. Neurology 2003, 60:947-951.
4. Foerch C, Singer OC, Neumann-Haefelin T, du Mesnil de Rochemont R, Steinmetz H, Sitzer M: Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction. Arch Neurol 2005, 62:1130-1134.
5. Bottiger BW, Moberg S, Glatzer R, Bauer H, Gries A, Barsch P, Motsch J, Martin E: Astroglial protein S-100 is an early and sensitive marker of hypoxic brain damage and outcome after cardiac arrest in humans. Circulation 2001, 103:2694-2698.
6. Rosen H, Rosenberg L, Herlitz J, Blomstrand C: Increased serum levels of the S-100 protein are associated with hypoxic brain damage after cardiac arrest. Stroke 1998, 29:787-792.
7. Weiss N, Sanchez-Peña P, Rochel S, Beaudieux JL, Colonne C, Coriat P, Puybasset L: Prognostic value of plasma S100B protein levels after subarachnoid aneurysmal hemorrhage. Anesthesiology 2006, 104:658-666.
8. Heizmann CW: S100B protein in clinical diagnostics: assay specificity. Clin Chem 2004, 50:249-251.
9. Gazzolo D, Michetti F, Bruschettini M, Marchese N, Lituanis M, Mangraviti S, Pedrazei E, Bruschettini P: Pediatirc concentrations of S100B protein in blood: age- and sex-related changes. Clin Chem 2003, 49:967-971.
10. Nygaard O, Langbak B, Romner B: Age and sex-related changes of S-100 protein concentrations in cerebrospinal fluid and serum in patients with no previous history of neurological disorder. Clin Chem 1997, 43:541-543.
11. Lounsbury S, Shoshan Y, Ovadia H, Pratik I, Hersch M, Ishayek E: Postoperative serum S100B levels predict postoperative brain damage in patients undergoing meningioma surgery. Crit Care Med 2006, 34:R141.
12. Stranjalis G, Korfas S, Psachoulia C, Boviatsis E, Kosyrias A, Protopappas D, Sakas DE: Serum S100B as an indicator of early postoperative deterioration after meningioma surgery. Clin Chem 2005, 51:202-207.
13. Bland JM, Altman DG: Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 1:307-310.
14. Mussack T, Klauss V, Ruppert V, Gippen-Steppert C, Biberthalier P, Schiemann U, Hoffmann U, Jochum M: Rapid measurement of S-100B serum protein levels by Elecsys S100 immunoassay in patients undergoing carotid artery stenting or endarterectomy. Clin Chem 2006, 39:349-356.
15. Wiesmann M, Missler U, Gottsch D, Gehring S: Plasma S-100B protein concentration in healthy adults is age- and sex-independent. Clin Chem 1998, 44:1056-1057.
16. Portela LV, Torc AB, Schaf DV, Ribeiro L, Nora DB, Walz R, Rotta LN, Silva CT, Busnello JV, Kapczinski F, Goncalves CA, Souza DO: The serum S100B concentration is age dependent. Clin Chem 2002, 48:950-952.
17. Barger SW, Van Eldik LJ: S100 beta stimulates calcium fluxes in glial and neuronal cells. J Neurotrauma 2002, 19:1302-1313.
18. Schafer BW, Heizmann CW: The S100 family of EF-hand calcium binding proteins: functions and pathology. Trends Biochem Sci 1996, 21:134-140.
19. Zimmer DB, Cornwall EH, Landar A, Song W: The S100 protein family: history, function, and expression. Brain Res Bull 1995, 37:417-429.
20. McAdory BS, Van Eldik LJ, Norden J: S100B, a neurotrophic protein that modulates neuronal protein phosphorylation, is upregulated during lesion induced collateral sprouting and reductive synaptogenesis. Brain Res 1998, 782:211-217.
21. Selinfridt RH, Barger SW, Prevette D, Moore BW, Bracken MB: Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. Biochim Biophys Acta 1999, 1450:191-231.
22. Bhattacharyya A, Oppenheim RW, Prevette D, Moore BW, Brackenbury R, Ratner N: S100 is present in developing chicken neurons and Schwann cells and promotes motor neuron survival in vivo. J Neurobiol 1992, 23:451-466.
23. Winningham-Major F, Staecker JL, Barger SW, Coats S, Van Eldik LJ: Neurite extension and neuronal survival activities of recombinant S100 beta proteins that differ in the content and position of cysteine residues. J Biol Chem 1992, 267:1007-1017.
24. Kilgman D, Marshak DR: Purification and characterization of a neurite extension factor from bovine brain. Proc Natl Acad Sci USA 1991, 88:3554-3558.
25. Donato R: Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. Biochim Biophys Acta 1999, 1450:191-231.
26. Rosen H, Rosenberg L, Herlitz J, Blomstrand C: Increased serum levels of the S-100 protein are associated with hypoxic brain damage after cardiac arrest. Stroke 1998, 29:473-477.
28. Kanner AA, Marchi N, Fazio V, Mayberg MR, Koltz MT, Siomin V, Stevens GH, Masaryk T, Aumayr B, Vogelbaum MA, Barnett GH, Janigro D: Serum S100beta: a noninvasive marker of blood-brain barrier function and brain lesions. Cancer 2003, 97:2806-2813.

29. Marchi N, Cavaglia M, Fazio V, Bhudia S, Hallene K, Janigro D: Peripheral markers of blood-brain barrier damage. Clin Chim Acta 2004, 342:1-12.

30. Ytrebo LM, Nedredal GI, Korvald C, Holm Nielsen OJ, Ingebrigtsen T, Romner B, Aarbakke J, Revhaug A: Renal elimination of protein S100beta in pigs with acute encephalopathy. Scand J Clin Lab Invest 2001, 61:217-225.

31. Fazio V, Bhudia SK, Marchi N, Aumayr B, Janigro D: Peripheral detection of S100beta during cardiothoracic surgery: what are we really measuring? Ann Thorac Surg 2004, 78:46-53.

32. Snyder-Ramos SA, Gruhlke T, Bauer H, Bauer M, Luntz AP, Motsch J, Martin E, Vahl CF, Missler U, Wiesmann M, Bottiger BW: Cerebral and extracerebral release of protein S100B in cardiac surgery patients. Anaesthesia 2004, 59:344-349.

33. Anderson RE, Hansson LO, Nilsson O, Liska J, Settergren G, Vaage J: Increase in serum S100A1-B and S100BB during cardiac surgery arises from extracerebral sources. Ann Thor Surg 2001, 71:1512-1517.

34. Zimmer DB, Van Eldik LJ: Tissue distribution of rat S100 alpha and S100 beta and S100-binding proteins. Am J Physiol 1987, 252:C285-289.

35. Suzuki F, Kato K, Nakajima T: Hormonal regulation of adipose S-100 protein release. J Neurochem 1984, 43:1336-1341.

36. Arcuri C, Giambanco I, Bianchi R, Donato R, Annexin V, annexin VI, S100A1 and S100B in developing and adult avian skeletal muscles. Neuroscience 2002, 109:371-388.

37. Gazzolo D, Marinoni E, Di Iorio R, Lituanu M, Bruschettini PL, Michetti F: Circulating S100B protein is increased in intrauterine growth retarded fetuses. Pediatr Res 2002, 51:215-219.

38. Wijnberger LD, Nikkels PG, van Dongen AJ, Noorlander CW, Mulder EJ, Schrama LH, Visser GH: Expression in the placenta of neuronal markers for perinatal brain damage. Pediatr Res 2002, 51:492-496.

39. Martens P, Raabe A, Johnsson P: Serum S-100 and neuron-specific enolase for prediction of regaining consciousness after global cerebral ischemia. Stroke 1998, 29:2363-2366.

40. Haaschini-Idrissi S, Auwera M Van der, Schiettecatte J, Ebinger G, Michetti F: Circulating S100B protein as early predictor of regaining consciousness after out of hospital cardiac arrest. Resuscitation 2002, 53:251-257.

41. Lee KH, Angus DC, Abramson NS: Cardiopulmonary resuscitation: What cost to cheat death? Crit Care Med 1996, 24:2046-2052.

42. Tiltford JM, Aitken ME, Anand KJ, Green JW, Goodman AC, Parker JG, Killingsworth JB, Fiser DH, Adelson PD: Hospitalizations for critically ill children with traumatic brain injuries: a longitudinal analysis. Crit Care Med 2005, 33:2074-2081.

43. Yangel SJ Jr, Rapport LJ, Hanks RA, Black KL: Long-term medical care utilization and costs among traumatic brain injury survivors. Am J Phys Med Rehabil 2005, 84:153-160.

44. Claesson L, Gosman-Hedstrom G, Johannesson M, Fagerberg B, Blomstrand C: Resource utilization and costs of stroke unit care integrated in a care continuum: A 1-year controlled, prospective, randomized study in elderly patients: the Goteborg 70+ Stroke Study. Stroke 2000, 31:2569-2577.

45. Porsdal V, Boysen G: Costs of health care and social services during the first year after ischemic stroke. Int J Technol Assess Health Care 1999, 15:373-384.

Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1472-6890/8/9/prepub